Derek DiRocco
Directeur/Bestuurslid bij MINERALYS THERAPEUTICS, INC.
Vermogen: 165 800 $ op 30-04-2024
Oorsprong van het eerstegraads netwerk van Derek DiRocco
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA.
162
| College/University | Other Consumer Services | 162 |
College of the Holy Cross (Massachusetts)
62
| College/University | Other Consumer Services | 62 |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA.
25
| Operating Division | Investment Managers | 25 |
19
| Public Company | Pharmaceuticals: Major | 19 |
| Public Company | Pharmaceuticals: Major | 18 | |
RA Capital Management LP
 RA Capital Management LP Investment ManagersFinance RA Capital Management LP (RA Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Peter Kolchinsky in 2004. RA Capital provides discretionary investment advisory services to Healthcare Funds and the Nexus Funds which are open only to certain financially sophisticated and high net-worth individuals and entities.
18
| Private Company | Investment Managers | 18 |
| Public Company | Pharmaceuticals: Major | 16 | |
| Public Company | Biotechnology | 14 | |
| Public Company | Biotechnology | 12 | |
Achilles Therapeutics UK Ltd.
 Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom.
10
| Public Company | Biotechnology | 10 |
| Public Company | Pharmaceuticals: Major | 9 | |
| Public Company | Pharmaceuticals: Major | 9 | |
Suzhou Connect Biopharma Co. Ltd.
 Suzhou Connect Biopharma Co. Ltd. Pharmaceuticals: MajorHealth Technology Suzhou Connect Biopharma Co. Ltd. develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products include CBP-307, CBP-174, and CBP-201. The company was founded by Zheng Wei and William Pan in 2012 and is headquartered in Taicang, China.
7
| Subsidiary | Pharmaceuticals: Major | 7 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Derek DiRocco via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| Yale University | College/University | Undergraduate Degree Doctorate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| Massachusetts Institute of Technology | College/University | Undergraduate Degree Doctorate Degree Undergraduate Degree Doctorate Degree Doctorate Degree | |
Merck Research Laboratories Massachusetts LLC
 Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Doctorate Degree Undergraduate Degree Undergraduate Degree Doctorate Degree Undergraduate Degree | |
| Princeton University | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| University of Cambridge | College/University | Doctorate Degree Graduate Degree Doctorate Degree Graduate Degree | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Founder Private Equity Investor Private Equity Investor Private Equity Investor | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Director/Board Member Corporate Officer/Principal | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
| SYNDAX PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member Director of Finance/CFO Chief Executive Officer | |
| RESEARCH ALLIANCE CORP. II | Financial Conglomerates | Chief Executive Officer Founder Director of Finance/CFO | |
Photys Therapeutics, Inc.
 Photys Therapeutics, Inc. Medical SpecialtiesHealth Technology Photys Therapeutics, Inc. is a company based in Cambridge, MA that was founded by Longwood Fund and Dr. Amit Choudhary of Brigham and Women's Hospital and the Broad Institute of MIT and Harvard. The company is advancing phosphorylation inducing chimeric small molecules (PHICs), a proprietary new class of bifunctional medicines that direct and repair protein phosphorylation to treat a range of diseases including cancer, immune, metabolic, and rare diseases. PHICs enhance the pairing of specific kinases with disease target proteins, inducing precise phosphorylation at native and/or non-native sites, modulating key functions including activation, stabilization, trafficking, localization, phospho-antigen presentation, inactivation, degradation, and interactions of proteins. The company's approach unlocks diverse classes of targets, developing a new class of medicines for precise control of protein function. The company was founded by Amit Choudhary, David Steinberg, Edward Holson, Lizzie Ngo. David Steinberg has been the CEO since incorporation. | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member | |
| ONCORUS, INC. | Biotechnology | Chairman Director/Board Member Director/Board Member | |
| The Johns Hopkins University | College/University | Undergraduate Degree Doctorate Degree Corporate Officer/Principal | |
| The University of Chicago | College/University | Doctorate Degree Masters Business Admin Undergraduate Degree | |
| University of Pennsylvania | College/University | Doctorate Degree Undergraduate Degree Corporate Officer/Principal | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| Stanford University | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree | |
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Investment Managers | Chief Executive Officer Private Equity Investor Private Equity Investor | |
Blue Earth Diagnostics Ltd.
 Blue Earth Diagnostics Ltd. Medical/Nursing ServicesHealth Services Blue Earth Diagnostics Ltd. engages in the development and commercialization of positron emission tomography imaging agents. It focuses on the molecular imaging diagnostics. The company was founded in March 2014 and is headquartered in Oxford, the United Kingdom. | Medical/Nursing Services | Chairman Director/Board Member Director/Board Member | |
| SPARK THERAPEUTICS, INC. | Biotechnology | Director/Board Member Founder | |
| Tuck School of Business at Dartmouth | College/University | Masters Business Admin Masters Business Admin | |
| University of Mumbai | College/University | Graduate Degree Graduate Degree | |
| ELIEM THERAPEUTICS, INC. | Biotechnology | Director/Board Member Chief Executive Officer | |
Sionna Therapeutics, Inc.
 Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | Medical/Nursing Services | Director/Board Member Chief Executive Officer | |
McKinsey & Co., Inc. (United Kingdom)
 McKinsey & Co., Inc. (United Kingdom) Investment ManagersFinance Part of McKinsey & Co., Inc., McKinsey & Co., Inc. (United Kingdom) is a consulting firm that helps UK manufacturers embrace new technologies for digital transformation and leadership. The company is based in London, UK. Ruben Schaubroeck, McKinsey Digital's new lead for the UK, Belgium, and Netherlands offices, spoke with Thomas Farrar, a manager of communications in the firm's UK office, about the importance of speed and pace for CEOs in this new growth journey. The British company works with organizations that pursue sustainability, inclusion, and economic growth, all at the same time, to achieve strategic foresight and built-in agility in the face of the COVID-19 pandemic and the new trading relationship with the EU. | Investment Managers | Corporate Officer/Principal Corporate Officer/Principal | |
| University of Virginia | College/University | Graduate Degree Undergraduate Degree | |
| Emory University | College/University | Undergraduate Degree Masters Business Admin | |
Azura Ophthalmics Pty Ltd.
 Azura Ophthalmics Pty Ltd. Medical SpecialtiesHealth Technology Azura Ophthalmics Ltd. develops therapies for meibomian gland dysfunction. It offers a portfolio of compounds in combination with a novel drug delivery platform to advance a portfolio of treatments for meibomian gland dysfunction. The company was founded by Yair Alster in 1980 and is headquartered in Tel Aviv, Israel. | Medical Specialties | Chairman Director/Board Member | |
Avilar Therapeutics, Inc.
 Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
| CELGENE | Biotechnology | President Corporate Officer/Principal | |
| Georgetown University | College/University | Graduate Degree Undergraduate Degree | |
UBS Securities LLC
 UBS Securities LLC Investment Banks/BrokersFinance UBS Securities LLC is an investment bank and registered broker/dealer headquartered in New York City. The firm was founded in 1998 as UBS Warburg LLC. They are a subsidiary of UBS Americas Holding LLC, ultimately held by UBS Group AG (SWX: UBSG, NYSE: UBS) in Switzerland. UBS Securities is a primary dealer in US Government securities and provides a full range of investment banking services which includes corporate finance, mergers and acquisitions, capital markets, trading and sales, fixed-income, equity research, private banking, underwriting and prime brokerage operations. The firm also provides advisory services and access to capital markets for corporate, institutional, intermediary and alternative asset management clients. | Investment Banks/Brokers | Analyst-Equity Corporate Officer/Principal | |
Flare Therapeutics, Inc.
 Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | Biotechnology | Director of Finance/CFO Director/Board Member | |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| St. Xavier's College | College/University | Undergraduate Degree Undergraduate Degree | |
| BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| ACHILLION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
| SPERO THERAPEUTICS, INC. | Biotechnology | Founder Director/Board Member | |
Clear Creek Bio, Inc.
 Clear Creek Bio, Inc. Pharmaceuticals: MajorHealth Technology Clear Creek Bio, Inc. engages in the development of therapies that target nucleotide synthesis pathways. The firm focuses on the differentiation blockade in cancer and suppress replication of RNA-based viruses. It uses pharmacodynamic markers to ensure that each patient gets the right drug at the correct dose. The company was founded by David T. Scadden, David B. Sykes, Burt A. Adelman, and Vikram Sheel Kumar in 2017 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Aliada Therapeutics, Inc.
 Aliada Therapeutics, Inc. BiotechnologyHealth Technology Aliada Therapeutics, Inc. is a neuroscience-focused company that aims to overcome the delivery hurdle in large molecule drug development. The company is based in Boston, MA. The company is advancing a generation of CNS therapeutics using its novel BBB crossing platform technology, which can efficiently transport a diverse array of therapeutic cargoes into the brain, resulting in enhanced downstream effectiveness. Aliada Therapeutics was founded by Sanjaya Singh, and the CEO is Adam Rosenberg. | Biotechnology | Chief Executive Officer Director/Board Member | |
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Pharmaceuticals: Generic | Chief Tech/Sci/R&D Officer Sales & Marketing | |
| VERTEX PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
| AUTOLUS THERAPEUTICS PLC | Biotechnology | Director/Board Member Director/Board Member | |
Quell Therapeutics Ltd.
 Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| SYNCONA LIMITED | Investment Trusts/Mutual Funds | Chief Executive Officer Corporate Officer/Principal | |
Neogene Therapeutics, Inc.
 Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY. | Biotechnology | Director/Board Member Director/Board Member |
Statistieken
Internationaal
| Verenigde Staten | 40 |
| Verenigd Koninkrijk | 8 |
| India | 3 |
| Israël | 3 |
Sectoraal
| Health Technology | 25 |
| Consumer Services | 17 |
| Finance | 7 |
| Health Services | 3 |
| Commercial Services | 2 |
Operationeel
| Director/Board Member | 510 |
| Corporate Officer/Principal | 194 |
| Independent Dir/Board Member | 153 |
| Chairman | 93 |
| Undergraduate Degree | 83 |
Sterkste connecties
| Insiders | |
|---|---|
| Srini Akkaraju Akkaraju | 54 |
| Luke Evnin | 42 |
| Edwin Moses | 35 |
| Kathy LaPorte | 34 |
| Martin Murphy | 33 |
| Peter Kolchinsky | 32 |
| Sarah Halton | 30 |
| Steven Altschuler | 27 |
| Michael Hayden | 27 |
| Briggs Morrison | 26 |
| Risa Stack | 25 |
| Olivier Litzka | 21 |
| Andrew Levin | 21 |
| Lota Zoth | 20 |
| Ann Rhoads | 19 |
- Beurs
- Insiders
- Derek DiRocco
- Bedrijfsconnecties
